Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy

Yan, Jianhua; Peng, Xifeng; Cai, Yulian; Cong, Wendong

doi:10.1016/j.jphotobiol.2018.04.033

Cited by 32 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the advantages offered by PLGA‐nanoparticles as an anti‐VEGF delivery system, it has been explored combining them with other nanoparticles or materials. Thus, nanoparticles based on conjugated iron oxide (Fe3O4)/polyethylene glycol‐ poly lactide‐co‐glycolide (PEG‐PLGA) have shown an efficient inhibition of the tube formation in the matrigel‐based assay method by using human umbilical vein endothelial cells 115 . Besides, the surface of PLGA nanoparticles can be modified to enhance its ocular performance.…”

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

“…Thus, nanoparticles based on conjugated iron oxide (Fe3O4)/polyethylene glycol-poly lactideco-glycolide (PEG-PLGA) have shown an efficient inhibition of the tube formation in the matrigel-based assay method by using human umbilical vein endothelial cells. 115 Besides, the surface of PLGA nanoparticles can be modified to enhance its ocular performance.…”

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

See 1 more Smart Citation

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, biological drug therapy for ocular angiogenesis treatment is based on the administration of anti‐VEGF agents via intravitreal route. The molecules approved with this purpose for ocular use include pegaptanib, ranibizumab, and aflibercept, whereas bevacizumab is commonly off‐label used in the clinical practice. The schedule dosage involves repeated intravitreal injections of anti‐VEGF agents to achieve and maintain effective concentrations in retina and choroids, which are administrated as solutions form. In this review article, we describe the features of different anti‐VEGF agents, major challenges for their ocular delivery and the nanoparticles in development as delivery system of them. In this way, several polymeric and lipid nanoparticles are explored to load anti‐VEGF agents with the aim of achieving sustained drug release and thus, minimize the number of intravitreal injections required. The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer‐reviewed published papers relevant to anti‐VEGF treatments and nanoparticles developed as ocular anti‐VEGF delivery system.

show abstract

Section: Nanoparticulate Systems For Bd Delivery Intended For Ocular mentioning

confidence: 99%

Section: Nanoparticles Based On Polymersmentioning

confidence: 99%

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Formica

Alfonso

Palma

2021

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

“… 158–210 Unspecified Zhang XP, et al 196 2018 Oxygen-induced retinopathy and corneal neovascularization Mice model Bevacizumab PLGA-nanoparticles Double-emulsion solvent evaporation Sustained release effects in vitro; increased half-life of drug and enhanced antiangiogenic efficacy in vivo; enhanced antiangiogenic properties in HUVEC. 133 Unspecified Yan J, et al 197 2018 Neovascular age-related macular degeneration Human umbilical vein endothelial cells Ranibizumab Ring opening polymerization, following addition of iron oxide nanoparticles PLGA-PEGylated magnetic nanoparticles Inhibition of the tube formation in HUVEC 5–10 Unspecified D. K. Karumanchi, et al 198 2018 Unspecified Rabbit model Bevacizumab Phospholipids and lipids of different chain size Lipid hydration and extrusion Sustained release effects in vivo; slow release and retained antibody activity after intravitreal administration in vivo. 120–385 Unspecified Mu H, et al 199 2018 CNV Rabbit model Bevacizumab Phospholipids and lipids of different chain size, albumin and PVA Double emulsification Sustained release effects in vivo; prolonged residency time in eye after intravitreal injection in vivo; enhanced antiangiogenic efficacy in a laser-induced CNV.…”

Section: Anti-vegf Agents and Novel Strategies Based On Nanotechnologymentioning

confidence: 99%

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Zhang¹,

Jiao²,

Niu³

et al. 2021

IJN

View full text Add to dashboard Cite

The complex drug delivery barrier in the eye reduces the bioavailability of many drugs, resulting in poor therapeutic effects. It is necessary to investigate new drugs through appropriate delivery routes and vehicles. Nanotechnology has utilized various nano-carriers to develop potential ocular drug delivery techniques that interact with the ocular mucosa, prolong the retention time of drugs in the eye, and increase permeability. Additionally, nano-carriers such as liposomes, nanoparticles, nano-suspensions, nano-micelles, and nano-emulsions have grown in popularity as an effective theranostic application to combat different microbial superbugs. In this review, we summarize the nano-carrier based drug delivery system developments over the last decade, particularly review the biology, methodology, approaches, and clinical applications of nano-carrier based drug delivery system in the field of ocular therapeutics. Furthermore, this review addresses upcoming challenges, and provides an outlook on potential future trends of nano-carrier-based drug delivery approaches in ophthalmology, and hopes to eventually provide successful applications for treating ocular diseases.

show abstract

“…Yan et al fabricated Fe 3 O 4 /PEGylated PLGA NPs hybridized with Ranibizumab and HUVEC cells identified to determine the long-term anti-angiogenic activity using tube formation in Matrigel assay. It was observed that such hybridization yielded improved inhibition of angiogenesis and no cytotoxicity compared to unloaded Fe 3 O 4 NPs [ 79 ]. There were attempts to improve the drug release from solid lipid implants (SLIs); in one study the authors reported that Ranibizumab was released for several months and no changes were found in the secondary structure [ 80 ].…”

Section: Advanced Therapeutics and Delivery Strategies For Namdmentioning

confidence: 99%

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Sarkar

Junnuthula

Dyawanapelly

2021

IJMS

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is the leading cause of vision loss in geriatric population. Intravitreal (IVT) injections are popular clinical option. Biologics and small molecules offer efficacy but relatively shorter half-life after intravitreal injections. To address these challenges, numerous technologies and therapies are under development. Most of these strategies aim to reduce the frequency of injections, thereby increasing patient compliance and reducing patient-associated burden. Unlike IVT frequent injections, molecular therapies such as cell therapy and gene therapy offer restoration ability hence gained a lot of traction. The recent approval of ocular gene therapy for inherited disease offers new hope in this direction. However, until such breakthrough therapies are available to the majority of patients, antibody therapeutics will be on the shelf, continuing to provide therapeutic benefits. The present review aims to highlight the status of pre-clinical and clinical studies of neovascular AMD treatment modalities including Anti-VEGF therapy, upcoming bispecific antibodies, small molecules, port delivery systems, photodynamic therapy, radiation therapy, gene therapy, cell therapy, and combination therapies.

show abstract

Development of facile drug delivery platform of ranibizumab fabricated PLGA-PEGylated magnetic nanoparticles for age-related macular degeneration therapy

Cited by 32 publications

References 25 publications

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology

Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective

Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)

Contact Info

Product

Resources

About